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Objective. To examine patient and medical characteristics which predict a missed diagnostic opportunity (MDO) for colorectal
cancer (CRC). Methods. The sample consisted of 252 patients diagnosed with Stages 1–4 CRC who were diagnosed in the prior
six months, had experienced symptoms prior to diagnosis, and were not diagnosed through routine screening. Systematic review
of all medical records prior to patients’ diagnosis was conducted. An MDO was defined as a clinical encounter where, even in
the presence of presumptive CRC symptoms, the CRC diagnostic process is not started. Results. 92 patients (36.5%) experienced
an MDO. Almost 80% of alternate diagnoses were other GI-GU diseases, including hemorrhoids and diverticulitis. Stomach pain,
anemia, and constipation were themost common symptoms experienced by theMDO group.These symptoms, and weight loss and
vomiting, were more likely to be noted in the charts of the MDO patients (𝑃 < 0.04). Independent risk factors for MDO included
age (<50) [OR = 2.29 (1.14–4.60), 𝑃 = 0.02] and female sex [OR = 2.19 (1.16–4.16), 𝑃 = 0.03]. Each additional physician seen, more
than doubled the MDO risk [OR = 2.05 (1.53–2.74), 𝑃 < 0.001]. Conclusions. Females, younger patients, and those consulting more
physicians were all more likely to experience an MDO. Continued increased training of physicians to enhance knowledge of who
is vulnerable to CRC is needed in addition to an increased focus to adherence to screening recommendations.
1. Introduction
Colorectal cancer (CRC) is the third most common cancer
in the world and fourth most common cause of cancer death
worldwide [1]. In the United States (US), it is also the third
most common cancer in both men and women, but the
second leading cause of cancer-related deaths [2]. Early stage
at diagnosis, associated with screening, is linked to better
prognosis and reduced mortality from CRC [3, 4]. When
identified at its earliest stages, reductions in morbidity and
costs have been identified [5]. However, only 40% of CRCs
are diagnosed at an early stage [6]. Therefore, recognition
of CRC symptoms as early as possible coupled with prompt
provision ofmedical attention for those who are experiencing
associated symptoms is critical.
Initial patient appraisal of CRC symptoms is frequently
delayed by underrecognition of symptom significance and
poor follow through with physician recommendations.
The literature defines patient appraisal delay as patients’
failure to recognize, acknowledge, or act on symptoms [7]. A
systematic review of the literature reports that appraisal delay
is the main patient factor associated with lengthier patient
times between experiencing a symptom and presenting it
to a practitioner [8]. There is some evidence to suggest
that demographic characteristics are associated with delayed
medical care seeking for CRC, and these include female
sex, younger age, lower education, and being a member of
a minority community [9–11]. However, more research is
needed to fully understand these factors.
Physicians may also delay the diagnosis by attributing
CRC symptoms to other less serious causes [12]. In one study,
diagnostic delay was reported to be more likely to occur
when a physician did not recognize symptoms as serious
[13]. This can occur with many CRC symptoms, including
the cardinal symptoms of rectal bleeding, anemia, abdominal
pain, weight loss, or changes in bowel habits; these symptoms
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are also indicative of many other, more common, but non-
life threatening diseases [14, 15]. Other factors contribut-
ing to diagnostic delay may include poor physician-patient
communication, resulting in physician or patient failure to
explore symptoms or obtain follow-up tests or referrals to
specialists [16]. Poor communication results when patients
understate orminimize symptoms or when physicians do not
thoroughly explore symptoms [13].The results of these factors
may result in missed diagnostic opportunities (MDOs) and
unintentional delay in initiating treatment [17]. Although, to
date, gender has not been shown to play a role in diagnostic
delay [11] of CRC, research on patient gender in physician-
patient communication suggests that female patients ask
more questions, present more symptoms, and give more
information in their medical history [18, 19].
There is some evidence to suggest longer CRC diagnostic
delay for ethnic minorities [20], and considerable research
to indicate differences in physician-patient communication
based on race/ethnicity, including less provision of biomed-
ical information, less psychosocial counseling, and less rela-
tionship building with non-White breast cancer patients [21],
as well as less patient-centered communication and less
positive affect towards African American patients [22].
This study examined the factors associated with MDOs.
Using a sample of recently diagnosed CRC patients in two
US states, data was reviewed and extracted from all medical
records prior to patients’ diagnoses. The study was designed
to specifically test whether individuals would be more likely
to have an MDO based on race and gender. Specifically, we
hypothesized that MDO would be more common in non-
Caucasians (potentially as a result of less patient-centered
visits) and in females (possibly because providing a large
amount of information increases the complexity of their
clinical presentation). We also examined whether patients
who had more symptoms and certain types of symptoms
would be less likely to have an MDO.The importance of this
to CRC is suggested by the study conducted by Astin et al.
(2011) suggesting certain symptoms and multiple symptoms
have increased positive predictive value [23].
2. Methods
2.1. Participants. Patients with a confirmed diagnosis of
Stages 1–4 CRC were identified, between 2008 and 2010,
through multiple sources to obtain complete ascertainment
of eligible patient cases, at the three academic and two
large private community oncology practices in Virginia and
Ohio. Case finding was conducted over a two-year period by
reviewing billing codes, obtaining cases from tumor board
ormultidisciplinary conferences, and by reviewing pathology
reports of patients prospectively. All patients diagnosed in the
six months prior to initial case identification were contacted
and phone screened. Inclusion criteria required that patients
have a diagnosis of CRC in the prior six months and have
experienced symptoms prior to their diagnosis. Patients
whose CRC was diagnosed as a result of routine screening
were excluded. The patients’ medical histories started at
their diagnoses in oncology practices and were then traced
back to their primary care physicians. Although case finding
occurred at oncology practices, the primary care physicians
who saw these patients were in private practice and fed into
many healthcare systems and followedmany different clinical
practice guidelines for the management of CRC symptoms.
This study was approved by all relevant Institutional Review
Boards and all participants provided informed consent.
2.2. Measurement. A systematic review of all patient medical
records, both electronic and paper, prior to CRC diagnosis
was conducted. As in previous studies [24], a detailed review
of progress notes, consultations, laboratory and pathology
reports, and additional relevant data in the records were
reviewed to evaluate the diagnostic process and assess it
for MDOs. Three raters were trained to conduct the review
under the auspices of one of the investigators (SHH), a board
certified family physician. The reviews were guided by a 20-
page coding manual. The coders extracted the information
according to the coding manual that operationalized the
definitions associatedwith each item; 20%were double coded
with discrepancies resolved via consensus. Records were
reviewed as far back as 8 years, when warranted.
The data extracted from the medical record included
patient sociodemographic characteristics, the number and
type of physicians seen (e.g., primary care, gastrointestinal
specialists, and obstetricians/gynecologists), type of physi-
cian in which the patient first reported symptoms, the
practice type (clinic, emergency department, etc.), specific
symptoms noted (abdominal pain, bowel changes, diarrhea,
constipation, indigestion, weight loss, blood in stool, ane-
mia, vomiting, rectal bleeding, and nausea), tests ordered
and/or performed (colonoscopy, fecal occult blood test, sig-
moidoscopy, barium enema, CT Scan, Magnetic Resonance
Imaging, Positron emission tomography, blood work, urine
analysis, digital rectal exam, other pelvic exams, endoscopy,
and hemoccult), date of first symptom noted, date of diagno-
sis, date of tests, date and type of definitive diagnostic test,
assessment of whether or not an MDO occurred, assessment
of whether watchful waiting occurred (whichwas categorized
underMDO), list of alternate diagnoses provided (if any), and
stage and staging information.
2.3. Main Measures
2.3.1. Outcome
Missed Diagnostic Opportunity. The definition of MDO,
adapted from the literature, is defined as a clinical encounter
where, even in the presence of presumptive illness symptoms
(in this case CRC), the diagnostic process is not started.
Rather, alternative evaluations are initiated or an incorrect
diagnosis is provided that ends the clinical evaluation process
for CRC [25, 26]. All charts were rigorously reviewed and
because we reviewed all visits for the CRC symptom cluster
that often crossed many visits, we were able to contextualize
the decisions made by physicians. Classification of an MDO,
which included inappropriate watchful waiting, was reviewed
by a board certified family physician (SHH). The outcome is
binary—the absence of MDO refers to the commencement
of a diagnostic process in response to symptoms while
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the presence of MDO involves the offering of alternative
evaluations or incorrect diagnoses that deviate from the
diagnostic process of CRC.
2.3.2. Covariates
(1) Symptoms. Symptoms were documented if noted in the
charts. Stomach or abdominal pain of any kind, bowel/stool
changes, diarrhea, constipation, blood in stool, rectal bleed-
ing, anemia/tiredness/weakness, weight loss, nausea, vom-
iting, and/or indigestion and additional, related symptoms,
were summed to represent a total symptom count per patient.
(2) Physician Factors.The number and specialty of physicians
consulted were recorded from the medical records.
(3) Patient Medicodemographic Characteristics. Age, gender,
race, education, income, insurance status, and history of
comorbid chronic disease were recorded. We also obtained
information on prior diagnostic tests leading to CRC diagno-
sis including colonoscopy and other screening tests.
2.4. Statistical Analysis. SPSS version 20.0 was employed
for analyses. Descriptive statistics were used to describe
the sample, alternative diagnoses received, and time to
diagnosis. Chi-square tests were used to determine signif-
icant bivariate relationships between the presence/absence
of MDO and patient medicodemographic characteristics,
physician characteristics, and presence/absence of specific
symptoms. Independent 𝑡-tests were used to test the rela-
tionships between presence/absence of MDO and the three
continuous variables measured: tumor size, number of total
symptoms, and number of total physicians seen for symptoms
prior to diagnosis. A stepwise logistic regression model was
conducted to examine the independent predictors of MDO,
controlling for sociodemographic characteristics. Sociode-
mographic characteristics shown to be significant in bivariate
analyses at𝑃 < 0.05were entered into the first block, followed
by medical characteristics (including presence/absence of
specific symptoms) and physician characteristics that were
shown to be significant in bivariate analyses at 𝑃 < 0.05.
Independent variables in the logistic regression model were
tested for significance using the Wald statistic at a 𝑃 value
level of 0.05. For summary purposes, Nagelkerke’s 𝑅2 (analog
to the 𝑅2 in linear regression) was used to indicate the extent
of variation explained and model fit.
3. Results
3.1. Patient Medicodemographic Characteristics. Of 495 pa-
tients screened, 66% (𝑁 = 303) were eligible to participate,
84% (𝑁 = 256) consented, and 252 completed the study. The
patient population consisted of 47.6% (𝑛 = 120) women and
53.6% (𝑛 = 135) Caucasian. Twenty-five percent (𝑛 = 64;
25.4%) were <50 years old, 47.6% (𝑛 = 120) had a high
school education or less, 44.0% (𝑛 = 111) had private health
insurance, and one-third of the sample (𝑛 = 84; 33.3%) was
diagnosed with earlier stage (I and II) disease. An MDO was
ascertained from the medical records of 92 patients (36.5%).
Table 1 shows the sociodemographic characteristics of CRC
patients with and without an MDO.
CRC patients with an identified MDO were significantly
more likely to be younger (less than age 50; 𝑋2 = 6.74,
𝑃 = 0.009), female (𝑋2 = 11.94, 𝑃 = 0.001), and a race
other than Caucasian (𝑋2 = 4.73, 𝑃 = 0.03) compared to
those without MDOs. The groups were similar with respect
to stage at time of diagnosis, tumor size, tumor depth, and
presence ofmetastases. Patients with anMDOhad an average
of 2.7 nodes positive for cancer at diagnosis compared to 2.0
for those without anMDO and this difference wasmarginally
significant (𝑃 = 0.05).
Table 2 shows the patient and physician characteristics of
the sample. Over half of the sample (57.1%; 𝑛 = 144) reported
having a comorbid chronic condition at the time of diag-
nosis (e.g., hypertension, diabetes, and cardiac conditions).
Although comorbidities were common in this sample, having
at least one comorbidity was not associated with an MDO. A
minority of patients (18.3%; 𝑛 = 46) had a colonoscopy or
other CRC screening tests (18.9%; 𝑛 = 47) prior to receiving
the diagnostic tests that led to the CRC diagnosis. Neither of
these factors was associated with MDO.
3.2. Symptoms. The average participant reported their symp-
toms to two physicians at separate visits at outpatient primary
care practices, emergency rooms (ER), and/or urgent care
centers (range 0–10). Those patients with MDOs reported
their symptoms to significantly more physicians than those
who did not (3.8 versus 2.4 physicians; 𝑡 = 7.00, 𝑃 < 0.001).
Sixty-eight percent (𝑛 = 171; 67.9%) of patients first com-
municated their symptoms to a primary care physician (PCP)
and 21.0% (𝑛 = 53) in the ER. Type of physician seen first was
not associatedwithMDO. Patientswithmore symptomswere
more likely to experience an MDO (4.7 versus 3.7; 𝑡 = 3.29;
𝑃 = 0.001) (see Table 2). Compared to those without an
MDO, those with an MDO were significantly more likely to
have the following symptoms noted in their medical records:
stomach pain (𝑋2 = 10.20, 𝑃 = 0.001), anemia (𝑋2 = 8.11,
𝑃 = 0.004), constipation (𝑋2 = 5.04, 𝑃 = 0.03), weight
loss (𝑋2 = 4.40, 𝑃 = 0.04), and vomiting (𝑋2 = 4.19, 𝑃 =
0.04) (see Table 3). No differences between groups were
noted with respect to other symptoms such as blood in stool
and change in bowel habits. The percentage of individuals
with each symptom who also experienced rectal bleeding
was 35.3% of those with stomach pain, 24.7% of those with
anemia, 34.7% of those with constipation, 32.6% of those
with weight loss, and 20.5% of those with vomiting. Rectal
bleeding was associated with anemia (𝑋2 = 5.70, 𝑃 = 0.017)
and vomiting (𝑋2 = 4.20, 𝑃 = 0.04) such that individuals
with anemia charted in their medical records were less likely
to have rectal bleeding charted than those without anemia
(24.7% versus 39.4%). Similarly, thosewith vomitingwere less
likely to have rectal bleeding reported (20.5% versus 36.5%).
3.3. Missed Diagnostic Opportunity, Alternative Diagnoses,
and Time to Diagnosis. Diagnostic delay was defined based
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Table 1: Sociodemographic and medical characteristics by missed diagnostic opportunity (𝑁 = 252).
Variable
Patients who had missed
diagnostic opportunity
Patients who did not have missed
diagnostic opportunity 𝑃 value
(𝑛 = 92; 36.5%) (𝑛 = 160; 63.5%)
Gender∗∗
Female 57 (62.0%) 63 (39.4%) 𝑃 = 0.001
Race∗
Caucasian 41 (44.6%) 94 (58.8%) 𝑃 = 0.03
Age∗
<50 32 (34.8%) 32 (20.0%) 𝑃 = 0.009
Education
<High school 18 (19.6%) 32 (20.0%)
𝑃 = 0.10
High school diploma 30 (32.6%) 40 (25.0%)
Some college 33 (35.9%) 50 (31.3%)
Bachelor’s degree and beyond 11 (12.0%) 37 (23.1%)
Declined to answer/do not know 0 (0.0%) 1 (0.6%)
Income
<$30,000 44 (47.8%) 61 (23.2%)
𝑃 = 0.22$30K–$75K 28 (30.4%) 44 (27.5%)
>$75K 18 (19.6%) 45 (28.1%)
Declined to answer/do not know 2 (2.3%) 10 (6.3%)
Health insurance
Private 41 (44.6%) 70 (43.8%)
𝑃 = 0.71Medicare 28 (30.4%) 43 (26.9%)
Medicaid, state insurance, or uninsured 23 (25.0%) 47 (29.4%)
Stage
1-2 25 (27.2%) 59 (36.9%)
𝑃 = 0.063-4 65 (70.7%) 101 (63.1%)
Unknown 2 (2.2%) 0
Tumor size 5.1 (2.1) 4.8 (2.0) 𝑃 = 0.14
∗
𝑃 < 0.05, ∗∗𝑃 < 0.01.
Table 2: Patient and physician factors associated with missed diagnostic opportunity.
Variable
Patients who had missed
diagnostic opportunity
Patients who did not have missed
diagnostic opportunity 𝑃 value
(𝑛 = 92) (𝑛 = 160)
Presence of comorbid condition 57 (62.0%) 87 (54.4%) 𝑃 = 0.24
Colonoscopy prior to the one leading to CRC diagnosis 19 (20.7%) 27 (16.9%) 𝑃 = 0.46
Other CRC screening tests prior to one leading to diagnosis 14 (15.4%) 33 (20.9%) 𝑃 = 0.29
Number of symptoms∗∗ 4.7 (2.6) 3.7 (2.2) 𝑃 = 0.001
Mean number of physicians seen∗∗∗ 3.8 (1.8) 2.4 (0.9) 𝑃 < 0.001
Type of physician first seen
Primary care physician 64 (69.6%) 107 (66.9%)
𝑃 = 0.81Emergency room physician 21 (22.8%) 32 (20.0%)
Other (specialist, nurse, etc.) 7 (7.6%) 21 (13.1%)
∗∗
𝑃 < 0.01, ∗∗∗𝑃 < 0.001.
BioMed Research International 5
Table 3: Common chart-documented symptoms of patients with a missed diagnostic opportunity (ordered by most frequently documented
in this group).
Symptom
Patients who had a missed
diagnostic opportunity
Patients who did not have missed
diagnostic opportunity 𝑃 value
(𝑛 = 92) (𝑛 = 160)
Stomach pain∗∗ 65 (70.7%) 80 (50.0%) 𝑃 = 0.001
Anemia∗∗ 46 (50.0%) 51 (31.9%) 𝑃 = 0.004
Constipation∗ 43 (46.7%) 52 (32.5%) 𝑃 = 0.03
Blood in stool 42 (45.7%) 75 (46.9%) 𝑃 = 0.85
Diarrhea 40 (43.5%) 52 (32.5%) 𝑃 = 0.08
Weight loss∗ 39 (42.4%) 47 (29.4%) 𝑃 = 0.04
Change in bowels/stool 37 (40.2%) 52 (32.5%) 𝑃 = 0.22
Indigestion 37 (40.2%) 46 (28.7%) 𝑃 = 0.06
Rectal bleeding 33 (35.9%) 52 (32.5%) 𝑃 = 0.59
Nausea 29 (31.5%) 34 (21.2%) 𝑃 = 0.07
Vomiting∗ 22 (23.9%) 22 (13.8%) 𝑃 = 0.04
∗
𝑃 < 0.05, ∗∗𝑃 < 0.01.
on the recommended refinements to The General Model
of Total Patient Delay [27] proposed by Andersen and
colleagues (1995) [28] stemming from earlier work by Safer
and colleagues (1979) [29]. Diagnostic delay was defined as
the time inmonths from the date of the first consultationwith
a healthcare provider for symptoms to the date of diagnosis.
Overall, the average diagnostic delay was 4.7 months (SD =
8.2).
Almost 80% of patients with an MDO were diagnosed
with an alternate GI-GU disease (𝑛 = 73; 79.3%), including
hemorrhoids (𝑛 = 26), diverticulitis (𝑛 = 15), urinary
tract infection (UTI, 𝑛 = 9), colitis/gastritis (𝑛 = 7),
gastroesophageal reflux disease (GERD, 𝑛 = 6), irritable
bowel syndrome (IBS, 𝑛 = 5), and/or gastroenteritis (𝑛 = 5)
(see Table 3). All of the individuals with alternate diagnoses
of UTI were women (100%, 𝑛 = 9), two out of three of those
diagnosed with diverticulitis were women (67%, 𝑛 = 15),
and the majority of those diagnosed with hemorrhoids (58%;
𝑛 = 15) were women. Approximately one out of four received
a non-GI-GU diagnosis (𝑛 = 21; 22.8%). For 26 patients
(28.3%), the review of the medical records indicated that the
physician engaged in watchful waiting, for example, when a
patient’s GI symptom complaints did not result in follow-up
testing and/or the only treatment recommendations involved
lifestyle or dietary changes.
Mean diagnostic delay for patients without an MDO
was 2.0 months (SD = 4.0), significantly shorter than 9.4
months (SD = 11.0) for patients with a documented MDO
(𝑡 = 8.21, 𝑃 < 0.001). Patients whose physicians did not
recommend watchful waiting averaged 3.7 months (SD =
6.6), significantly shorter than 13.6 months (SD = 13.6) for
those whose physicians engaged in watchful waiting (𝑡 =
5.40, 𝑃 < 0.001). Patients receiving a GI-GU related alternate
diagnosis averaged 9.0 months (SD = 9.9) to diagnosis
while thosewho received a non-GI-GUdiagnosis needed 10.5
months (SD = 11.5) to be diagnosed (see Table 4).
3.4. Logistic Regression Model Predicting Missed Diagnostic
Opportunity. The final model (Table 5) demonstrates that
patients who had an MDO were more than twice as likely to
be less than 50 years [OR = 2.29 (1.14–4.60), 𝑃 = 0.02] and
female [OR = 2.19 (1.16–4.16), 𝑃 = 0.03]. For each physician
seen, the likelihood of MDO more than doubled [OR =
2.05 (1.53–2.74), 𝑃 < 0.001]. Number or type of symptoms
was not independently predictive of MDO. Nagelkerke’s 𝑅2
of 0.36 indicates a moderate relationship between the set of
predictors in the model and MDO.
4. Discussion
Routine screening is important for early diagnosis of CRC.
However, many Americans are noncompliant with screen-
ing guidelines and screening is not perfect; only 65% of
Americans, age 50 and older, have ever undergone any
type of screening test for CRC [30]. Interestingly, screen-
ing compliance rates are similar in universal care and/or
socialized health care systems [31]. For instance, only 55–
60% of individuals aged 60 invited to participate in the Bowel
Cancer Screening Programme in England returned their first
FOBT [32]. Recent studies also estimate that colonoscopy
may miss detecting lesions [33]. Moreover, routine testing is
not recommended for those under 50 years of age; therefore,
symptom recognition remains an important component of
early detection and treatment. We found evidence that being
younger (<50) and female, as well as being assessed by more
than one physician, were independent risk factors for MDO.
Furthermore, over the course of diagnosis, stomach pain,
anemia, and constipation were more frequently documented
in the group of patients with MDO. These, of course, are
symptoms common to other illnesses and anemia is especially
prevalent in menstruating women and associated with gyne-
cological ailments. Lastly, almost 80% of misdiagnoses were
alternate GI-GU diseases, most commonly, hemorrhoids
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Table 4: Alternate diagnoses recorded in medical chart for symptoms indicative of CRC (𝑛 = 92).
Alternate diagnosis+ 𝑛 Mean time to diagnosis inmonths
Median time to diagnosis
in months
No diagnosis, missed opportunity/watchful waiting 26 13.6 (13.6) 9.2
GI-GU disease 73 9.0 (9.9) 6.3
Hemorrhoids 26
Diverticulitis 15
Urinary tract infection (UTI) 9
Colitis/Gastritis 7
Gastroesophageal reflux disease (GERD) 6
Irritable bowel syndrome (IBS) 5
Gastroenteritis 5
Kidney stones 4
OB/GYN disease (cyst, neoplasm, fibroids) 3
Pregnancy 2
Chronic kidney disease 2
Small bowel disease (cancer, obstruction) 2
Gallbladder 2
Crohn’s disease 1
Chronic dysphagia 1
Chronic constipation 1
Hernia 1
Dyspepsia 1
H. pylori 1
Appendicitis 1
Prostatitis 1
Anal fissure 1
Syphilis 1
HIV infection 1
Non-GI-GU diagnoses 21 10.5 (11.5) 9.3
Cardiovascular 7
Respiratory 6
Back/skeletal 5
Side effects of medications 4
Osteoarthritis 2
Fibromyalgia 1
Insomnia 1
+Some patients had more than one alternate diagnosis; 11 had both GI-GU and non-GI-GU alternate diagnoses. Because of this no tests of significance were
performed.
and diverticulitis, and that diagnosis with a non-GI-GU
disease was associated with even longer diagnostic delay.
Individuals with anMDOexperienced nearly double the time
to diagnosis, and patients whose physicians chose watchful
waiting experienced triple the time.
Few studies have simultaneously examined patient and
physician factors influencing MDO in CRC; these studies
have investigated physician delay in referring patients for
further investigation of symptoms. Like this study, other
studies indicate that older age leads to quicker referrals and
more prereferral consultations are associated with younger
age and ethnic minority status [11]. This supports the results
of the present study in which those under age 50 are 2.3
times more likely to experience an MDO. In univariate
analyses, patients of a race other than Caucasian were more
likely than Caucasians to have an MDO, although these
results were not significant in the multivariable model. Our
findings strongly suggest that gender plays a significant
role, as 62% of the MDO group were female. Follow-
up analyses found that most of the alternate diagnoses
of hemorrhoids, diverticulitis, and UTIs were made in
females.
BioMed Research International 7
Table 5: Multivariate model examining predictors of missed diagnostic opportunity.
Variable 𝛽 Wald Odds ratio (95% confidence interval) 𝑃 value
Gender: female∗ 0.79 5.79 2.19 (1.16–4.16) 𝑃 = 0.02
Race: African American 0.31 0.96 1.37 (0.73–2.57) 𝑃 = 0.36
Age < 50∗ 0.83 5.41 2.29 (1.14–4.60) 𝑃 = 0.02
Number of physicians seen∗∗∗ 0.72 23.31 2.05 (1.53–2.74) 𝑃 < 0.001
Number of symptoms experienced 0.07 1.02 1.07 (0.94–1.23) 𝑃 = 0.31
Stomach pain 0.54 2.34 1.07 (0.86–3.41) 𝑃 = 0.26
Anemia 0.11 0.11 1.12 (0.58–2.17) 𝑃 = 0.74
Constipation 0.17 0.22 1.18 (0.59–2.35) 𝑃 = 0.64
Weight loss 0.17 0.23 1.18 (0.60–2.33) 𝑃 = 0.63
Vomiting −0.26 0.32 0.77 (0.32–1.87) 𝑃 = 0.57
∗
𝑃 < 0.05, ∗∗∗𝑃 < 0.001.
Some of this study’s findings are not consistent with
previous work in the field, however. For instance, patients
who experienced an MDO average one more documented
symptom than those who did not experience an MDO.
Mariscal et al. report that, as the number of symptoms
presented increases, time from initial consultation to hospital
admission for digestive tract cancers decreases [34]. The fact
that higher number of symptoms are related to MDO but
not stage suggests that patients who experienced an MDO in
this study may be presenting with a more complex clinical
picture. The types of symptoms these patients present with,
and the time course of theirmultisymptompresentation,may
account for this discrepancy, especially given that this sample
excluded patients diagnosed through screening colonoscopy.
These patients were excluded because of the study’s intent
to examine the role that symptom presentation plays in the
diagnostic process. Our study indicates that anemia, stomach
pain, and constipation were the most common symptoms of
the group with MDOs. In European cohorts, iron-deficiency
anemia [26, 35] and rectal bleeding [26] were the primary
symptoms most often associated with MDO for CRC diag-
nosis. In a US study, Singh et al. also found that anemia
was the most common symptom associated with MDOs for
CRC diagnosis and longest referral time for an endoscopic
procedure [25]. It was also associated with two-thirds of
MDOs for CRC in a Veterans Administration sample [36].
Of note in our study is that, in multivariable analyses, anemia
was not a significant independent predictor of MDO. Finally,
a systematic review of the diagnostic value of symptoms for
CRC in primary care concluded that investigation of anemia
in primary care patients is warranted, regardless of whether
other symptoms are present [23].
Seeing an additional physician for CRC symptoms was
associated with twice the risk of MDO. Although this finding
may be intuitive, as increases in seeking consultations with
new physicians provides more opportunity/risk for possible
MDO, to our knowledge, the importance of this factor as
related to MDO and/or diagnostic delay has not been previ-
ously documented. Our sample was comprised exclusively on
those individuals who experienced symptoms prior to diag-
nosis who were primarily diagnosed with later stage disease,
whereas many other studies examine all patients diagnosed
with CRC and focus on physician screening behaviors and
probably drove these results.We believe it is a strength, of this
study, as those diagnoses through screening are a different
segment of the CRC population. Furthermore, physician
training, resources, and screening guideline incentives may
differ across healthcare systems and regions, thus additional
investigation of the factors related toMDO, in other contexts,
is warranted.
It is possible that some physicians may have made verbal
diagnoses or recommendations for follow-up that were not
documented in the medical records and would not have
been captured using the chart reviewmethodology. Although
we compiled lists of all possible physicians seen by patients
and followed-up with practices identified via documented
referrals, it is possible we may have missed some, thus
influencing this study’s findings. Although every effort was
taken to ensure that the case notes were rigorously reviewed,
the timing of specific symptoms and symptom combinations
in relation to the MDO was not extracted. Future studies,
especially in the context of the U.S. healthcare system, and
in context of the high variability in community practice, are
warranted to fully explore these aspects.
In summary, our study suggests that greater training
of physicians could be helpful for dispelling stereotypes
about who is vulnerable to CRC. Within the population,
men are only slightly more susceptible to CRC than women
[1]; however, women were twice as likely to experience an
MDO. Younger patients (<50 years) are also more likely to
experience anMDO, giving rise to some concern that current
CRC screening recommendations are leading physicians to
erroneously discount the possibility of CRC in symptomatic
younger patients. A recent study supports these findings, that,
even lacking a family history, CRC is not insignificant [37].
Moreover, the incidence rate of CRC in this age group is
increasing and now accounts for 12% of all cases of CRC
[37, 38]. Given the fact that a physician has, on average, six
to 18 minutes to conduct a clinical evaluation and provide
follow-up recommendations (depending on the country) and
that physicians feel they need more time to spend with their
patients [39], future research and policy are needed to better
understand and assist physicians with the demands placed on
them that may result in rushed visits and ultimately anMDO.
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Looking at the results as a whole, there are potential
lessons for clinical practice. First, although it is important
to understand the average characteristics of a patient pop-
ulation, the focus in the physician-patient encounter is the
patient and not his/her sociodemographic group. Although
90% of new cases of CRC are in patients over 50 years of age,
over 14,000 individuals less than age 50 in theUS alonewill be
diagnosedwithCRC annually [40].Therefore, some vigilance
concerning patients under the age of 50 is warranted. In this
study, younger patients weremore likely to have greater times
to diagnosis. In addition,womenwere alsomore likely to have
greater diagnostic delay, perhaps because CRC is thought
to be more prevalent in men. Another source of diagnostic
difficulty was demonstrated by greater time to diagnosis
for patients with more symptoms. Although intuitively it
would seem that more symptoms would provide more sign
posts leading toward the CRC diagnosis, the greater number
of symptoms, coupled with the nonspecific nature of these
symptoms, seemed to add complexity rather than clarity to
making a diagnosis. We posit that when patients were seen
by more physicians—perhaps because the patient was not
satisfied with the treatment provided by the initial physician
or because they did not have easy or regular access to the
health system—the discontinuity in care led to greater time
to diagnosis. This is an issue that bears further exploration.
It may be that some physicians are confronting aHobson’s
choice between interacting with the “whole” patient or just
asking for the facts, although both pieces are likely important.
This study is yet another indication that quality care takes
time, skill, and the participation of both the patient and the
physician.
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